Summary
This 2017 study, published in European Urology, examined the clinical outcomes of chemotherapy administered after immune checkpoint inhibition in patients with metastatic urothelial cancer. The research appears to address whether prior immunotherapy alters the efficacy of subsequent conventional chemotherapy, a question of relevance to treatment sequencing in advanced bladder cancer. Without access to the full abstract, the precise magnitude of effects and patient cohort characteristics cannot be confirmed.
UK applicability
Findings would be applicable to UK oncology practice, as urothelial cancer treatment protocols and immunotherapy access are similar across Western European health systems. However, applicability depends on whether the cohort and sequencing patterns reflect NHS treatment pathways at the time of publication.
Key measures
Response rate to chemotherapy (as suggested by partial response or complete response criteria); progression-free and overall survival; treatment sequencing outcomes
Outcomes reported
The study examined response rates to subsequent chemotherapy in patients with metastatic urothelial cancer who had previously received immune checkpoint inhibitor therapy. As suggested by the title, the research evaluated whether prior immunotherapy affected tumour responsiveness to conventional chemotherapy regimens.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.